US FDA accepts MS drug Lemtrada resubmission for review
US FDA accepts MS drug Lemtrada resubmission for review
The US Food and Drug Administration (FDA) has accepted for review the Genzyme's resubmission of supplemental Biologics License Application (sBLA) seeking approval of Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis. A six-month review period has been assigned for the Lemtrada sBLA. Genzyme expects FDA action on the sBLA in the fourth quarter...... Read More - http://www.ms-uk.org/lemtrada
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1844 Views
-
Last post by frodo
-
- 0 Replies
- 1185 Views
-
Last post by NHE
-
- 0 Replies
- 1675 Views
-
Last post by frodo
-
- 0 Replies
- 1211 Views
-
Last post by frodo
-
- 1 Replies
- 1690 Views
-
Last post by frodo
-
- 0 Replies
- 1970 Views
-
Last post by NHE
-
- 0 Replies
- 2234 Views
-
Last post by NHE
-
- 0 Replies
- 1059 Views
-
Last post by frodo
-
- 1 Replies
- 1380 Views
-
Last post by NHE